Fresenius Medical Care highlights new renal research and innovation at ERA Congress 2026

Rhea-AI Summary

Fresenius Medical Care (NYSE:FMS) will showcase new renal research and digital innovation at the ERA Congress 2026 in Glasgow and virtually, June 3‑6.

Highlights include evidence-based hemodiafiltration studies, AI-driven tools for dialysis care, patient-centered outcomes research, and a preview of the kinexus home dialysis digital platform.

News Market Reaction – FMS

-0.09%

-0.09% Session close to close

In the May 27 session, FMS declined 0.09%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement highlights Fresenius Medical Care’s focus on evidence-based dialysis, AI-driven to...

Analysis

This announcement highlights Fresenius Medical Care’s focus on evidence-based dialysis, AI-driven tools, and home-care innovation. New research on hemodiafiltration outcomes, patient-reported recovery times, and AI models for peritoneal dialysis dropouts underscores a data-centric approach to kidney care. The preview of the kinexus home dialysis platform adds to a broader innovation pipeline. In light of prior updates on profitability, capital returns, and home hemodialysis growth, investors may watch how these initiatives scale across 3,539 clinics and impact patient outcomes for 4.5 million individuals.

Key Figures

Global dialysis patients: 4.5 million patients Dialysis clinics: 3,539 clinics Clinic patients: approx. 290,000 patients +1 more

4 metrics

Global dialysis patients 4.5 million patients Patients worldwide regularly undergoing dialysis treatment

Dialysis clinics 3,539 clinics Global network of Fresenius Medical Care dialysis clinics

Clinic patients approx. 290,000 patients Patients treated across Fresenius Medical Care clinics

ERA Congress dates June 3–6, 2026 European Renal Association (ERA) Congress 2026 in Glasgow

Historical Context

5 past events · Latest: May 21 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
May 21	AGM and strategy update	Positive	+1.4%	AGM highlighted higher profitability, leverage reduction and enhanced shareholder returns.
May 20	Management reappointment	Positive	+0.3%	CFO Martin Fischer reappointed, reinforcing financial discipline and transformation strategy.
May 05	Q1 2026 earnings	Negative	-10.9%	Mixed Q1 with organic growth but lower reported income and net income declines.
Feb 24	2025 full-year earnings	Positive	-7.8%	Strong 2025 earnings, margin in target band, higher EPS and buyback plans.
Jan 15	Home dialysis expansion	Positive	+1.1%	Growth in U.S. home hemodialysis and launch of NxStage VersiHD with GuideMe.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

News tied to operational strength and capital returns often saw positive alignment, while a strong 2025 earnings release drew a negative reaction, showing occasional divergence on fundamentally strong updates.

Recent Company History

Over recent months, Fresenius Medical Care has emphasized profitability gains, capital returns, and innovation. At the May 21 AGM, the company highlighted higher margins, lower leverage, a higher dividend and a €1 billion buyback, with shares up 1.35%. Q1 2026 results on May 5 showed organic revenue growth but lower reported income, and the stock fell 10.86%. Strong 2025 earnings on Feb 24 led to a 7.85% decline, contrasting with positive reactions to innovation and home hemodialysis adoption earlier in the period.

Key Terms

hemodiafiltration, hemodialysis, peritoneal dialysis, artificial intelligence, +3 more

7 terms

hemodiafiltration medical

"hemodiafiltration (HDF) research reinforces Fresenius Medical Care's continued leadership"

A blood-cleaning treatment for people whose kidneys fail that combines two actions — one that washes away small dissolved wastes and another that filters out larger particles and excess fluid — using a machine and a sterile replacement fluid. It matters to investors because adoption of this technique affects demand for dialysis machines, disposable supplies, treatment costs and patient outcomes, so shifts in use can change revenues and clinical competitiveness like an equipment upgrade improving both speed and results.

hemodialysis medical

"In a real-world analysis, hemodiafiltration was associated with lower three-year mortality risk than hemodialysis"

Hemodialysis is a medical treatment that cleans a person’s blood when their kidneys can no longer do the job, by routing blood through a machine that filters out waste, excess fluid and adjusts salt levels—think of it as an external, mechanical kidney. It matters to investors because it drives demand for specialized machines, replacement filters, clinics, trained staff and related drugs, and is sensitive to reimbursement rules, treatment volumes and advances that can change costs or market share.

peritoneal dialysis medical

"AI-based model predicting Peritoneal Dialysis Dropouts Is Associated with Lower Hospitalization Rates"

Peritoneal dialysis is a kidney replacement treatment that uses the lining of the abdomen as a natural filter: a sterile fluid is put into the belly, left to absorb waste and excess fluid, then drained away, and the cycle repeats. It matters to investors because it drives demand for machines, disposable solutions and training services, affects healthcare costs and reimbursement trends, and can shift patient care from hospitals to home, altering market opportunities.

artificial intelligence technical

"application of artificial intelligence (AI) to improve patient outcomes"

Artificial intelligence is the ability of computers and machines to perform tasks that typically require human thinking, such as understanding language, recognizing patterns, or making decisions. For investors, it matters because AI can enhance efficiency, uncover new insights, and enable smarter strategies, potentially impacting the value and performance of companies that develop or utilize this technology.

ai-based model technical

"Clinics' Utilization of an AI-Based Model Predicting Peritoneal Dialysis Dropouts"

An ai-based model is a computer system that learns patterns from large amounts of data and uses those patterns to make predictions or decisions, like a digital brain that improves with experience. For investors it matters because these models can speed analysis, spot trends or risks earlier, and automate decisions—potentially improving forecasts and cutting costs—but they can also introduce errors or bias that affect performance and compliance.

large-language model technical

"A High‑Precision Large‑Language Model Approach for Abstract Screening in Systematic Reviews"

A large-language model is a type of artificial intelligence that has learned to read and generate human-like text by studying vast amounts of written material, acting like a very well-read digital assistant that can summarize, answer questions, draft messages, or generate ideas. Investors care because it can change how companies operate and compete — boosting productivity, cutting costs, creating new products and revenue streams, and introducing risks around accuracy, regulations, and labor needs.

systematic reviews technical

"large‑language model approach for abstract screening in systematic reviews"

A systematic review is a careful, structured summary of all available studies on a specific question—often about a medical treatment or technology—using predefined rules to find, evaluate and combine results so conclusions are less likely to be skewed by one-off studies. For investors, it acts like a thorough audit of the evidence: it reduces uncertainty about a drug’s or product’s real effects and helps assess regulatory, clinical and commercial risks before making funding or valuation decisions.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

• Hemodiafiltration (HDF) research reinforces Fresenius Medical Care's continued leadership in advancing evidence-based dialysis care and treatment personalization
• New research focuses on applying real-world evidence, patient-centered outcomes and artificial intelligence across dialysis modalities and continuity of kidney care
• A preview of kinexus, a unified digital platform intended to support home dialysis programs by connecting therapy management and care workflows

BAD HOMBURG, Germany, May 27, 2026 /PRNewswire/ -- Fresenius Medical Care (FME), the world's leading provider of products and services for individuals with kidney diseases, presents new research highlighting ongoing innovation at the European Renal Association (ERA) Congress 2026, June 3-6 in Glasgow, Scotland, and virtually. The Company highlights advancements including new hemodiafiltration research that reaffirm its leadership in evidence based and personalized dialysis care, real-world evidence to strengthen patient centered outcomes across dialysis modalities, and the application of artificial intelligence (AI) to improve patient outcomes.

"Fresenius Medical Care is focused on the research that can meaningfully advance the standard of care for people living with kidney disease," said Charles Hugh-Jones, Global Chief Medical Officer at Fresenius Medical Care. "At ERA Congress 2026, we continue demonstrating our Company's leadership in evidence-based hemodiafiltration research and present abstracts covering the use of real-world evidence, patient-centered outcomes and artificial intelligence that are designed to help clinicians make better informed decisions and support patients across multiple care settings."

FME's Global Medical Office and Renal Research Institute (RRI) teams present multiple abstracts across a range of critical topics in nephrology, demonstrating how data, artificial intelligence, and patient-centered outcomes are shaping the future of kidney care.

Key presentations include:

• Impact of Matching and Weighting Strategy on Patient Retention and 3‑Year Mortality in Real‑World Hemodialysis and Hemodiafiltration: In a real-world analysis, hemodiafiltration was associated with lower three-year mortality risk than hemodialysis, with consistent results across different comparison methods.
• The Association Between Patient‑Reported Dialysis Recovery Time and Missed Treatments: Hemodialysis patients who reported longer recovery times after treatment also had a higher number of missed treatments.
• Clinics' Utilization of an AI-Based Model Predicting Peritoneal Dialysis Dropouts Is Associated with Lower Hospitalization Rates: Clinics with higher use of an AI-based dashboard for identifying peritoneal dialysis patients at risk of dropping out saw lower all-cause hospitalization rates.
• A High‑Precision Large‑Language Model Approach for Abstract Screening in Systematic Reviews: GPT-5 may help researchers sort through large numbers of research studies by identifying ones that are most relevant.

In addition to these presentations, FME leaders and researchers will also be available onsite at Booth #C.210 and the Renal Research Institute's Booth #C.410 to discuss research insights, clinical collaborations, and innovations in kidney care.

As part of its broader innovation portfolio highlighted at the Congress, FME previews kinexus, a unified digital platform for home dialysis. Designed as a single, integrated ecosystem, kinexus brings together remote therapy management and operational workflows to help simplify care processes for healthcare teams and support high-quality, personalized care for patients dialyzing at home.

To learn more about FME's presence at ERA, please click here.

About Fresenius Medical Care:
Fresenius Medical Care is the world's leading provider of products and services for individuals with renal diseases of which around 4.5 million patients worldwide regularly undergo dialysis treatment. Through its network of 3,539 dialysis clinics, Fresenius Medical Care provides dialysis treatments for approx. 290,000 patients around the globe. Fresenius Medical Care is also the leading provider of dialysis products such as dialysis machines or dialyzers. Fresenius Medical Care is listed on the Frankfurt Stock Exchange (FME) and on the New York Stock Exchange (FMS).

For more information visit the company's website at www.freseniusmedicalcare.com.

Disclaimer:
This release contains forward-looking statements that are subject to various risks and uncertainties. Actual results could differ materially from those described in these forward-looking statements due to various factors, including, but not limited to, changes in business, economic and competitive conditions, legal changes, regulatory approvals, results of clinical studies, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. These and other risks and uncertainties are detailed in Fresenius Medical Care's reports filed with the U.S. Securities and Exchange Commission. Fresenius Medical Care does not undertake any responsibility to update the forward-looking statements in this release.

Huma Therapeutics Limited is the digital health platform partner and legal manufacturer of kinexus. Fresenius Medical Care Deutschland GmbH acts as the authorized distributor.

For more information about Huma Therapeutics Limited visit the company's website at www.huma.com.

Media contact
Christine Peters
T +49 160 60 66 770
christine.peters@freseniusmedicalcare.com 

Kirsten Stratton
T +1 781 929 8096
Kirsten.stratton@freseniusmedicalcare.com 

Contact for analysts and investors
Dr. Dominik Heger
T +49 6172 609 2525
dominik.heger@freseniusmedicalcare.com 

www.freseniusmedicalcare.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/fresenius-medical-care-highlights-new-renal-research-and-innovation-at-era-congress-2026-302783113.html

SOURCE Fresenius Medical Care Holdings, Inc.

FAQ

What will Fresenius Medical Care (FMS) present at ERA Congress 2026?

Fresenius Medical Care will present new renal research on hemodiafiltration, patient-centered outcomes, and AI applications in dialysis. According to Fresenius Medical Care, multiple abstracts from its Global Medical Office and Renal Research Institute will highlight data-driven advances in evidence-based and personalized kidney care.

How does Fresenius Medical Care (FMS) research compare hemodiafiltration and hemodialysis in 3-year mortality?

In a real-world analysis, hemodiafiltration was associated with lower three-year mortality risk than hemodialysis. According to Fresenius Medical Care, these results were consistent across different matching and weighting comparison methods, reinforcing the role of hemodiafiltration in evidence-based dialysis care.

What is the kinexus digital platform previewed by Fresenius Medical Care (FMS) at ERA 2026?

Kinexus is a unified digital platform intended to support home dialysis programs. According to Fresenius Medical Care, kinexus integrates remote therapy management with operational workflows to simplify care processes for healthcare teams and support high-quality, personalized home dialysis for patients.

How is Fresenius Medical Care (FMS) using artificial intelligence in dialysis care?

Fresenius Medical Care is highlighting AI-based tools to improve dialysis outcomes. According to Fresenius Medical Care, clinics using an AI dashboard to predict peritoneal dialysis dropouts showed lower all-cause hospitalization rates, and a high-precision large-language model is being explored for abstract screening in systematic reviews.

What patient-centered outcomes research is Fresenius Medical Care (FMS) sharing at ERA Congress 2026?

The company is presenting data linking dialysis recovery time to missed treatments. According to Fresenius Medical Care, hemodialysis patients reporting longer post-treatment recovery times also had a higher number of missed treatments, underscoring the importance of patient-reported outcomes in optimizing dialysis care.

Who is partnering with Fresenius Medical Care (FMS) on the kinexus digital health platform?

Huma Therapeutics is the digital health platform partner and legal manufacturer of kinexus. According to Fresenius Medical Care, Fresenius Medical Care Deutschland serves as the authorized distributor, while Huma provides the underlying digital health technology for the home dialysis ecosystem.